Overview
Medically supervised ibogaine treatment involves administering ibogaine in a clinical setting with full medical screening, continuous monitoring especially cardiac, and emergency capability, typically for opioid use disorder OUD, other substance use disorders, and increasingly PTSD/TBI-related psychiatric symptoms. It can produce rapid, large reductions in withdrawal, craving, and psychiatric symptoms after one or a few doses, but carries non-trivial risks of QT prolongation, arrhythmia, and death, so strict medical protocols are essential. Clinic-level examples such as Experience Ibogaine Treatment Center are therefore best evaluated through their screening standards, cardiac monitoring, and emergency capability.[1]
Below is a detailed dossier organized by topic. Background and History of Medically Supervised Ibogaine 1.1 Discovery of anti-addictive effects - Ibogaine is an indole alkaloid from Tabernanthe iboga, long used in West African Bwiti rituals.[2]
- Its anti-addictive properties were first publicly described by Howard Lotsof in 1962, after he and other individuals noted abrupt interruption of heroin dependence following single ibogaine sessions. - Through the 1980s–1990s, Lotsof promoted clinical development and helped initiate early human case series and open-label treatments.[3]
From underground to medicalized treatment - Because ibogaine was placed in Schedule I in the U.S. in 1970 no accepted medical use, high abuse potential, clinical development largely moved outside the U.S., especially to Mexico, Caribbean e.g., St. Kitts, New Zealand, Brazil, and later Canada.[4]
Research findings
N depressive and trauma-related symptoms. - Two fatalities were described within the 24 included studies, and other deaths have been reported in broader literature, largely linked to neuro- and cardiotoxic effects and comorbidities.[2]
- The authors emphasize that “rigorous study designs within medical settings are necessary to warrant safe application, monitoring, and, possibly, medical intervention”. This review is a key evidence base for medically supervised ibogaine, highlighting both efficacy signals and the need for strict medical oversight.[3]
Medically Supervised Ibogaine for Opioid Use Disorder and Other SUDs 4.1 Observational study: Crossroads Treatment Center Mexico One of the most detailed medically supervised programs is Crossroads Tijuana, Mexico: - Study: “Subjective effectiveness of ibogaine treatment for problematic opioid use” Authors: Thomas Kingsley Brown, Kenneth R. Journal/Year: Journal of Psychopharmacology, 2018.[5]
- Setting: Crossroads Treatment Center, a medically supervised ibogaine clinic. - Population: Individuals with opioid dependence, including heroin and other opioids. Crossroads operated in the same medical-tourism environment as other programs offering ibogaine treatment in Tijuana, where ECG monitoring, IV fluids, and exclusion criteria became key safety markers.[4]
The study is observational; n is typically reported around a few dozen participants exact n and dose details are in the full article, but the abstract highlights outcomes. - Treatment protocol: - Ibogaine administered under live cardiac monitoring, IV saline and electrolytes.
Safety considerations
Id withdrawal exact inclusion criteria detailed in registry. - Dosing: Structured mg/kg titration; specific dose steps are within the protocol.[3]
- Endpoints: Safety/tolerability adverse events, vital signs, ECG, reduction in withdrawal scores, craving, and opioid use. - This trial exemplifies fully regulated, medically supervised ibogaine administration aimed at FDA-like standards.[5]
Medically Supervised Ibogaine for PTSD, Depression, Anxiety, and TBI 5.1 Stanford/Ambio Life Sciences Veterans TBI Study Mexico This is the most prominent recent medically supervised ibogaine trial in psychiatry. - Study: Open-label exploratory clinical test of ibogaine for TBI-related psychiatric symptoms Lead: Nolan Williams and team at Stanford University; treatment administered at Ambio Life Sciences clinic in Mexico.[4]
- Publication/Year: Results reported in Stanford Medicine news and Brain & Behavior Research Foundation article in 2024. Military veterans with traumatic brain injury TBI and comorbid PTSD, major depression, anxiety, and disability.
- n is described as “a small preliminary trial”; media sources suggest a sample on the order of 20–30 participants exact n in full paper, but summary emphasizes robustness of effects. - Setting and medical supervision: - Participants traveled to Ambio Life Sciences clinic in Mexico, where ibogaine is legally administered.[6]
Legal and clinical context
Ring is itself a model of enhanced cardiac-risk mitigation. Qualitative work on long-lasting psychological benefits - Article: “Reconsidering Ibogaine for the treatment of severe mental illness” title per Sciencedirect index.[5]
The abstract notes a qualitative study involving 73 individuals, documenting long-lasting psychological benefits such as enhanced emotional regulation, increased meaning in life, and personal growth after ibogaine treatment. - While not strictly limited to medically supervised contexts, many participants were treated in clinical or quasi-clinical programs, suggesting that structured settings support both safety and integration.[4]
Safety, Adverse Events, and Cardiac Risk Management 6.1 Fatalities and serious complications - The Drews et al. systematic review found two ibogaine-related fatalities within the 24 included clinical/therapeutic studies, and notes additional deaths reported in broader case reports.
- BCSP summarizes: “Ibogaine can be dangerous. There are numerous reports in the scientific literature of people having fatal cardiac events after taking ibogaine.[6]
Other side effects range from nausea and tremors to less commonly psychosis and mania, seizures, and comas.” - Risk factors identified across literature include: - Pre-existing structural heart disease. - Long QT syndrome or baseline QTc prolongation.[7]
Evidence limitations
Land and other jurisdictions - UC Berkeley BCSP notes that some ibogaine clinics operate where ibogaine is legal or in a gray area, including New Zealand. Kitts Caribbean, Deborah Mash’s program operated with government permission and clinical oversight, reportedly without serious adverse events across hundreds of treatments.[4]
In nearly all such jurisdictions, medically supervised treatment is the norm for legitimate programs, differentiating them from underground or non-medical settings. Typical Clinical Dosing Protocols Specific mg/kg doses are sometimes underreported in lay summaries, but standard medically supervised ibogaine protocols generally follow patterns that can be inferred from clinical reports and practice guidelines.
Flood dose for addiction interruption - Common full treatment doses in addiction clinics: - 10–20 mg/kg oral ibogaine HCl, often split: - Test dose e.g., 2–3 mg/kg. - Main dose e.g., 8–12 mg/kg after stability confirmed.[6]
- Optional booster 2–5 mg/kg depending on response and tolerability. - Treatment lasts 12–24 hours of acute experience, with lingering effects up to 36 hours.[7]
- In the Crossroads study, rapid resolution of withdrawal within 34 hours is consistent with flood-dose protocols. Exact dosing in individual published studies—including mg/kg breakdown and acute vs.[8]